In a study from Ramanan et al., baricitinib proved safe and effective for reducing the time to flare and frequency of flare in patients aged 2–18 years with juvenile idiopathic arthritis.
Baricitinib, an oral JAK1/JAK2 inhibitor approved to treat RA in adults, is being investigated as a possible treatment for hospitalized patients with COVID-19…
Recent research found that RA patients who began treatment with baricitinib experienced greater improvement from baseline than patients who began treatment with methotrexate…
The phase 3, RA-BEAM study found RA patients who were switched from adalimumab to baricitinib experienced improvements in disease control even in the absence of an adalimumab washout. In the study, the change was not associated with an increase in adverse events or infections…
A recent study found that baricitinib improved symptoms of arthritis and rash in patients with active SLE, while maintaining a safety profile consistent with previous findings…
The FDA Arthritis Advisory Committee has recommended the approval of 2 mg baricitinib (but not in a 4 mg dose) for treating adults with moderate to severe active RA…